🔗 Share this article

While the US continues making sweeping adjustments to its vaccination guidelines, an unexpected name has surfaced unexpectedly: Dr. Tracy Beth Høeg, a US-based sports medicine doctor and public health researcher who initially gained attention by expressing skepticism about Covid shots throughout the pandemic and has zeroed in on potential fatalities after COVID-19 vaccination in her brief position at the FDA.

Planned Shifts to Childhood Immunization Program

Health officials had intended to announce major changes to the pediatric vaccine schedule earlier this month, synchronizing the US with the Danish vaccine program, sources say – a significant shift that would put the US out of step with much of the international standard with insufficient data for public health gain. The announcement has been delayed until the new year.

Instead of Vinay Prasad, Tracy Beth Høeg is listed to address the audience at the gathering. She was newly appointed acting director of the FDA’s drug evaluation center, the fifth person to run the office this calendar year.

A Shift at the FDA

The acting appointment could signify a tighter collaboration between the pharmaceutical and vaccine centers as Dr. Høeg and Prasad strengthen their influence at the agency – and it suggests a greater focus upon dismantling previously authorized immunizations at the FDA.

Høeg has frequently advocated for ending some childhood vaccine recommendations in the US to become more in line with Denmark's approach, a nation with nationalized medicine and a number of inhabitants roughly the size of the state of Wisconsin.

To date comments, she has persisted in emphasizing on vaccines – usually the purview of Dr. Prasad, head of the FDA’s vaccine center – instead of drug regulation.

Doubts Over Expertise

Dr. Høeg has no apparent background in medication creation, regulation or administrative roles, which has been standard for former heads of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a top consultant to the FDA chief and the vaccine center since spring.

“She doesn’t seem to have the necessary background” for leading the pharmaceutical oversight division, remarked a neurologist and psychiatrist. “She’s never run a randomized controlled trial. She has no expertise in running a large organization. She lacks background in drug approvals.”

Former heads of the center would “grasp laws and regulations and the science of drug development”, commented Dr. Janet Woodcock. “Clearly, she doesn’t have the kind of background that former directors who ran CBER have had.”

This division has an vast portfolio at the agency, she pointed out.

“Everybody just zeroes in on the new drug program, but the generic drug division authorizes a multitude of off-brand pharmaceuticals. There is also a biologic copycat branch, OTC medication office and other areas, and all of those have to be looked after,” she said. “The area you don’t keep your eye on, that’s the thing that I always told people is going to cause problems.”

There is also, a substantial leadership aspect to the role, which supervises over 5,000 employees. “It’s a enormous leadership role, if you execute it properly,” Woodcock concluded.

Response and Contentious Programs

When asked about inquiries about Høeg’s qualifications and whether this appointment indicates increased cooperation among agency officials on immunizations, a press secretary responded that the “questions rely on flawed presumptions”.

“This background aligns with the responsibilities of her role,” the official said, noting the period Høeg spent advising the agency head on “pharmaceutical safety and approval science, including computerized risk analysis and shot safety tracking”.

As acting director, Høeg inherits the agency head's controversial priority voucher program, a disputed rapid drug-approval program that reportedly troubled her preceding directors. “By what process are these therapies being picked for this fast-track system? Who is making the decisions?” Howard said. “There’s a lot of secrecy going on at the regulatory body right now.”

Broadly speaking, he remarked, “the agency looks to be trending towards laxer rules of all drugs, with the exception of shots.”

Public Track Record on Vaccines

Concerning vaccines, Høeg has a more documented, if troubling, past, critics have noted. She authored a study using unverified public submissions to assess the incidence of heart inflammation following COVID-19 vaccination. She consulted for the state of Florida surgeon general Joseph Ladapo, who allegedly have modified findings to suggest COVID-19 vaccines are riskier than they are.

Included in her “desired changes” for the current government included changing regulations for recently developed shots and halting “optional” immunizations, she remarked post-election on a podcast. At the FDA, Høeg has allegedly proposed preventing adolescent males from obtaining COVID-19 vaccinations.

“She is an all-around true believer who begins with her preconceived notions and works backwards to accommodate the science in a very deceptive, fraudulent manner,” Howard stated.

Taking Control and a “Push for Payback”

Høeg joined fellow contrarians, {like|